Literature DB >> 6511244

Advantages of integrated trials for performing multiple Phase II studies.

G B Weiss, J A Hokanson.   

Abstract

Phase II trials can be conducted in an integrated fashion that minimizes assignment of patients to potentially ineffective treatments. The technique allows definitions of response to include survival; earlier identification of more effective drugs; and completion of more Phase II studies in a given time period. It also encourages investigators to analyse results promptly. Because the analysis of each trial is independent, the statistical power of the analysis of results is retained. Identified shortcomings of the method include the need for a central mechanism to assign patients to treatment, the need for several drugs to be tested, physicians' uncertainty about which drug a particular patient will receive, and the increased time it may take to complete an individual trial.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6511244     DOI: 10.1007/bf00171595

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  12 in total

1.  Early studies of anticancer agents in humans: the question of sample size.

Authors:  E A GEHAN
Journal:  Cancer Chemother Rep       Date:  1962-02

Review 2.  Adaptive treatment assignment methods and clinical trials.

Authors:  R Simon
Journal:  Biometrics       Date:  1977-12       Impact factor: 2.571

3.  Predictive probability early termination plans for phase II clinical trials.

Authors:  J Herson
Journal:  Biometrics       Date:  1979-12       Impact factor: 2.571

4.  Practical side of multistage clinical trials for screening new agents.

Authors:  J Herson
Journal:  Cancer Treat Rep       Date:  1983-01

5.  Etoposide in small cell lung cancer resistant to prior chemotherapy.

Authors:  R F Asbury; J Rubins; J M Bennett
Journal:  Cancer Treat Rep       Date:  1983-10

6.  KSTAGE: an interactive computer program for designing phase II clinical trials using predictive probability.

Authors:  E N Atkinson; B W Brown; J Herson
Journal:  Comput Biomed Res       Date:  1982-06

7.  Phase II study of chlorozotocin in non-small cell carcinoma of the lung.

Authors:  C J Cornell; D Hoth; T F Pajak
Journal:  Cancer Treat Rep       Date:  1981 Jul-Aug

8.  Statistical considerations for pilot studies.

Authors:  D Schoenfeld
Journal:  Int J Radiat Oncol Biol Phys       Date:  1980-03       Impact factor: 7.038

9.  Phase II trial of PALA in hypernephroma and urinary bladder cancer.

Authors:  R B Natale; A Yagoda; D P Kelsen; R J Gralla; R C Watson
Journal:  Cancer Treat Rep       Date:  1982-12

10.  Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575, generation I).

Authors:  R H Creech; C R Mehta; M Cohen; M Donavan; R Sponzo; B A Mason; R T Skeel; F Ahmed; P J Creaven; H J Lerner; E Foelsch
Journal:  Cancer Treat Rep       Date:  1981 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.